CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

16 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
CROS1G2032R AND CD74::ROS1 FusionPredictiveSupportsResistanceLung AdenocarcinomaCrizotinibAwad et al., 2013
DROS1G2032R AND CD74::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCabozantinibKatayama et al., 2015
DROS1G2032R AND CD74::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCabozantinib,ForetinibDavare et al., 2015
DROS1G2032R AND CD74::ROS1 FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinib,Brigatinib,Ceritinib,AZD3463Davare et al., 2015
DROS1G2032R AND v::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaLorlatinibZou et al., 2015
DROS1L2026M AND CD74::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaLorlatinibZou et al., 2015
CROS1G2032R AND CD74::ROS1 FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibSong et al., 2015
DROS1L2155S AND CD74::ROS1 FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaForetinib,Crizotinib,ALK Inhibitor TAE684Song et al., 2015
DROS1G2032R AND SLC4A4::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaDS-6501bKatayama et al., 2019
DROS1L2026M AND CD74::ROS1 FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibZou et al., 2015
DROS1G2032R AND CD74::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaForetinibSong et al., 2015
DROS1L2026M AND CD74::ROS1 FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibSong et al., 2015
DROS1L2026M AND CD74::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaForetinibSong et al., 2015
DROS1G2101A AND CD74::ROS1 FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibSong et al., 2015
DROS1G2101A AND CD74::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaForetinibSong et al., 2015
CROS1G2032RPredictiveSupportsResistanceLung AdenocarcinomaCrizotinibAwad et al., 2013